What are the Challenges in Targeting Efflux Pumps?
Despite the potential benefits, targeting efflux pumps in cancer therapy comes with several challenges:
Specificity: Many efflux pump inhibitors are not specific and can affect normal cells, leading to toxicity. Redundancy: Cancer cells often express multiple types of efflux pumps, making it difficult to completely inhibit drug efflux. Resistance Mechanisms: Cancer cells can develop alternative resistance mechanisms, such as altering drug targets or increasing drug metabolism.